An experimental gene therapy based on the prime editing technique could become an effective treatment for alternating hemiplegia of childhood, a severe and currently incurable rare disease. David ...

While U.S. government cost-cutting seems to be the Trump administration’s priority that consumes all others, some Republican ...

With more-than-satisfying phase III data in hand, Minneapolis-based Celcuity Inc. is eyeing an NDA submission in the fourth quarter of this year for gedatolisib (geda) in breast cancer. Shares of the ...

Trinity Biotech plc recently unveiled CGM+, an AI-native, wearable biosensor that goes beyond traditional continuous glucose monitors and tracks glucose levels, cardiovascular activity and body ...

An advisory committee for the U.S. Centers for Medicare & Medicaid Services endorsed a series of patient- and ...

The U.S. FDA has cleared Zymeworks Inc.’s IND application for ZW-251, a novel glypican-3 (GPC3)-targeted antibody-drug ...

Researchers from Biotiche Drug Discovery Srl and collaborators have discovered that modulating the activity of a specific ...

Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and ...

The chaperone protein Hsp90 is overexpressed in many cancers, where it helps protect and drive cell proliferation by ...

Pharmaceutical exports from the EU to the U.S. are facing a leap in tariffs from zero duty to 15%, following the trade deal between EU Commission President Ursula von der Leyen and U.S. President ...

Researchers at the Fred Hutchinson Cancer Research Center found that autoantibodies targeting the exoproteome reshaped ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...